Novartis’s Inclisiran Unscathed As Arrowhead Falls Short
But NASH Candidate Generates Interest
Executive Summary
Arrowhead’s drug has failed to match inclisiran’s performance, but its RNAi platform has other promising candidates.
You may also be interested in...
Arrowhead Gets $120m From GSK For First-In-Class NASH RNAi Candidate
GSK enters the NASH race with a mid-stage candidate while Arrowhead gets to focus its R&D spending on candidates it may bring to market itself.
$1bn Deal Boosts Takeda, Arrowhead’s Liver Disease And RNAi Ambitions
Takeda's global deal for one of US RNAi specialist's lead assets follows recent promising clinical results in serious disorder with no current therapeutic options.
Omicron Clouds Novavax’s Delayed COVID-19 Vaccine Debut
Novavax has already gained its first emergency use authorization for its COVID-19 vaccine, but doubts remain about its manufacturing and Omicron readiness.